LEGEND BIOTECH CORP-ADR (LEGN) Stock Fundamental Analysis

NASDAQ:LEGN • US52490G1022

17.58 USD
-0.48 (-2.66%)
At close: Feb 13, 2026
17.8 USD
+0.22 (+1.25%)
After Hours: 2/13/2026, 8:21:30 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to LEGN. LEGN was compared to 522 industry peers in the Biotechnology industry. While LEGN seems to be doing ok healthwise, there are quite some concerns on its profitability. LEGN shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year LEGN has reported negative net income.
  • In the past year LEGN has reported a negative cash flow from operations.
  • LEGN had negative earnings in each of the past 5 years.
  • LEGN had a negative operating cash flow in each of the past 5 years.
LEGN Yearly Net Income VS EBIT VS OCF VS FCFLEGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

  • With an excellent Return On Assets value of -14.01%, LEGN belongs to the best of the industry, outperforming 80.69% of the companies in the same industry.
  • LEGN has a Return On Equity of -23.73%. This is amongst the best in the industry. LEGN outperforms 80.31% of its industry peers.
Industry RankSector Rank
ROA -14.01%
ROE -23.73%
ROIC N/A
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
LEGN Yearly ROA, ROE, ROICLEGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

  • The Gross Margin of LEGN (60.55%) is better than 78.39% of its industry peers.
  • The Profit Margin and Operating Margin are not available for LEGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LEGN Yearly Profit, Operating, Gross MarginsLEGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • LEGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LEGN has more shares outstanding
  • Compared to 5 years ago, LEGN has more shares outstanding
  • The debt/assets ratio for LEGN is higher compared to a year ago.
LEGN Yearly Shares OutstandingLEGN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
LEGN Yearly Total Debt VS Total AssetsLEGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • LEGN has an Altman-Z score of 4.31. This indicates that LEGN is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 4.31, LEGN is doing good in the industry, outperforming 72.08% of the companies in the same industry.
  • A Debt/Equity ratio of 0.26 indicates that LEGN is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.26, LEGN is doing worse than 66.16% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z 4.31
ROIC/WACCN/A
WACC11.74%
LEGN Yearly LT Debt VS Equity VS FCFLEGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 2.86 indicates that LEGN has no problem at all paying its short term obligations.
  • LEGN has a Current ratio of 2.86. This is in the lower half of the industry: LEGN underperforms 65.77% of its industry peers.
  • LEGN has a Quick Ratio of 2.80. This indicates that LEGN is financially healthy and has no problem in meeting its short term obligations.
  • LEGN has a worse Quick ratio (2.80) than 64.44% of its industry peers.
Industry RankSector Rank
Current Ratio 2.86
Quick Ratio 2.8
LEGN Yearly Current Assets VS Current LiabilitesLEGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • LEGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.11%, which is quite impressive.
  • LEGN shows a strong growth in Revenue. In the last year, the Revenue has grown by 74.74%.
  • Measured over the past years, LEGN shows a very strong growth in Revenue. The Revenue has been growing by 59.90% on average per year.
EPS 1Y (TTM)32.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.65%
Revenue 1Y (TTM)74.74%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%69.99%

3.2 Future

  • The Earnings Per Share is expected to grow by 32.56% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, LEGN will show a very strong growth in Revenue. The Revenue will grow by 32.33% on average per year.
EPS Next Y-0.34%
EPS Next 2Y54.88%
EPS Next 3Y51.39%
EPS Next 5Y32.56%
Revenue Next Year66.44%
Revenue Next 2Y55.76%
Revenue Next 3Y46.66%
Revenue Next 5Y32.33%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
LEGN Yearly Revenue VS EstimatesLEGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
LEGN Yearly EPS VS EstimatesLEGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • LEGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • LEGN is valuated quite expensively with a Price/Forward Earnings ratio of 46.39.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of LEGN indicates a rather cheap valuation: LEGN is cheaper than 90.44% of the companies listed in the same industry.
  • LEGN is valuated expensively when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 46.39
LEGN Price Earnings VS Forward Price EarningsLEGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LEGN Per share dataLEGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • LEGN's earnings are expected to grow with 51.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y54.88%
EPS Next 3Y51.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • LEGN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LEGEND BIOTECH CORP-ADR

NASDAQ:LEGN (2/13/2026, 8:21:30 PM)

After market: 17.8 +0.22 (+1.25%)

17.58

-0.48 (-2.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-09
Inst Owners47.87%
Inst Owner Change-95.67%
Ins Owners0.08%
Ins Owner ChangeN/A
Market Cap3.23B
Revenue(TTM)908.96M
Net Income(TTM)-239.99M
Analysts83.2
Price Target68.76 (291.13%)
Short Float %21.43%
Short Ratio7.26
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-260.82%
Min EPS beat(2)-366.2%
Max EPS beat(2)-155.43%
EPS beat(4)1
Avg EPS beat(4)-127.99%
Min EPS beat(4)-366.2%
Max EPS beat(4)147.06%
EPS beat(8)2
Avg EPS beat(8)-64.68%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.59%
Min Revenue beat(2)-2.02%
Max Revenue beat(2)9.2%
Revenue beat(4)2
Avg Revenue beat(4)2.04%
Min Revenue beat(4)-2.02%
Max Revenue beat(4)9.2%
Revenue beat(8)4
Avg Revenue beat(8)1.55%
Revenue beat(12)6
Avg Revenue beat(12)20.38%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.23%
PT rev (3m)-8.64%
EPS NQ rev (1m)-53.3%
EPS NQ rev (3m)-12.37%
EPS NY rev (1m)0.92%
EPS NY rev (3m)6.06%
Revenue NQ rev (1m)-1.53%
Revenue NQ rev (3m)-1.19%
Revenue NY rev (1m)-0.38%
Revenue NY rev (3m)-0.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 46.39
P/S 3.55
P/FCF N/A
P/OCF N/A
P/B 3.19
P/tB 3.19
EV/EBITDA N/A
EPS(TTM)-1.29
EYN/A
EPS(NY)0.38
Fwd EY2.16%
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS4.95
BVpS5.51
TBVpS5.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.01%
ROE -23.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.55%
FCFM N/A
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.25%
Cap/Sales 2.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.86
Quick Ratio 2.8
Altman-Z 4.31
F-Score4
WACC11.74%
ROIC/WACCN/A
Cap/Depr(3y)97.56%
Cap/Depr(5y)226.91%
Cap/Sales(3y)9.76%
Cap/Sales(5y)32.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.65%
EPS Next Y-0.34%
EPS Next 2Y54.88%
EPS Next 3Y51.39%
EPS Next 5Y32.56%
Revenue 1Y (TTM)74.74%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%69.99%
Revenue Next Year66.44%
Revenue Next 2Y55.76%
Revenue Next 3Y46.66%
Revenue Next 5Y32.33%
EBIT growth 1Y45.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.06%
EBIT Next 3Y57.01%
EBIT Next 5Y37.37%
FCF growth 1Y61.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.38%
OCF growth 3YN/A
OCF growth 5YN/A

LEGEND BIOTECH CORP-ADR / LEGN FAQ

What is the ChartMill fundamental rating of LEGEND BIOTECH CORP-ADR (LEGN) stock?

ChartMill assigns a fundamental rating of 4 / 10 to LEGN.


Can you provide the valuation status for LEGEND BIOTECH CORP-ADR?

ChartMill assigns a valuation rating of 2 / 10 to LEGEND BIOTECH CORP-ADR (LEGN). This can be considered as Overvalued.


Can you provide the profitability details for LEGEND BIOTECH CORP-ADR?

LEGEND BIOTECH CORP-ADR (LEGN) has a profitability rating of 2 / 10.


What is the financial health of LEGEND BIOTECH CORP-ADR (LEGN) stock?

The financial health rating of LEGEND BIOTECH CORP-ADR (LEGN) is 4 / 10.